StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab r&d expenses

Research and development expenses are spending on new products and technology.

BioNexus Gene Lab's R&D Expenses for the twelve months ending Jun 30, 2026 was $54.13K, up 3.0% year over year. For fiscal 2025 it was $50.67K, up 6.6% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$50.67K+6.6%
FY2024Dec 31, 2024$47.51K-13.6%
FY2023Dec 31, 2023$54.98K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$13.67K+8.9%
Q1 FY2026Mar 31, 2026$14.49K+19.3%
Q4 FY2025Dec 31, 2025$11.10K-36.2%
Q3 FY2025Sep 30, 2025$14.88K+42.5%
Q2 FY2025Jun 30, 2025$12.56K+53.2%
Q1 FY2025Mar 31, 2025$12.14K+5.8%
Q4 FY2024Dec 31, 2024$17.40K–
Q3 FY2024Sep 30, 2024$10.44K–
Q2 FY2024Jun 30, 2024$8.20K–
Q1 FY2024Mar 31, 2024$11.48K–

More BioNexus Gene Lab figures

See a number that looks wrong?